A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold

ConditionCommon Cold
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-65
SponsorTasly Pharmaceutical Group Co., Ltd

About this trial

To further evaluate the efficacy and safety of Antiwei granule in the treatment of common cold (wind-cold syndrome)

Eligibility criteria

Qualifiers

It met the diagnostic criteria of common cold in western medicine;

In accordance with the TCM syndrome differentiation standard of wind-cold syndrome;

Male and female patients aged 18 to 65 years;

The disease duration at enrollment was ≤48 h;

Disqualifiers

Complicated with influenza, pneumonia, suppurative tonsillitis, acute tracheobronchitis, acute pharyngeal conjunctivitis, acute viral or herpetic pharyngitis, acute viral or herpetic laryngitis;

Patients who had been infected with 2019-ncov in the past and still had symptoms such as cough and fatigue for nearly 3 months after the antigen turned negative;

Primary ciliary dyskinesia syndrome, other acute onset nasal diseases (such as allergic rhinitis, chronic rhinitis, acute and chronic sinusitis, etc.), previous nasal surgery or radiotherapy of the nasopharynx with nasal mucosal dysfunction;

Patients with chronic respiratory diseases (such as chronic obstructive pulmonary disease, interstitial lung disease, etc.), asthma, and tuberculosis;

Trial design

Treatments tested in this trial

  • Antiwei Granules
  • Antiwei Granules Placebo

Treatment groups

480 Participants
are divided into 2 treatment groups